Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Atebimetinib

Small molecule · Inhibitor of MEK1 (MAP2K1) and MEK2 (MAP2K2) · developed by Immuneering

Phase 3 Most advanced trial

IMRX Developer

2 Registered trials

What is Atebimetinib?

Atebimetinib is an orally bioavailable inhibitor of MEK1 and MEK2 kinases. It selectively binds to and inhibits MEK1/2 activity, preventing activation of downstream effector proteins and transcription factors in the RAS/RAF/MEK/ERK pathway. It is studied in advanced solid tumors including pancreatic adenocarcinoma, melanoma, and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: MEK1 (MAP2K1), MEK2 (MAP2K2)
Mechanism: Inhibitor of MEK1 (MAP2K1) and MEK2 (MAP2K2)
Pathways: MAPK/ERK, RAS/RAF/MEK/ERK
Therapy area: Oncology
Developer: Immuneering Corporation (IMRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: TEL9243A3N

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07562152	Phase 3	Pancreatic Cancer	Recruiting	IMRX
NCT05585320	Phase 1/2	Advanced Solid Tumor	Active not recruiting	IMRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorMalignant Melanoma (Cutaneous)Non-small Cell Lung Cancer (NSCLC)Pancreatic AdenocarcinomaPancreatic Adenocarcinoma MetastaticPancreatic CancerPancreatic Cancer MetastaticPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)PDACPDAC - Pancreatic Ductal Adenocarcinoma

Other drugs acting on MAP2K1 / MAP2K2

Mirdametinib FDA approved Trametinib FDA approved IMM-6-415 Phase 1/2 PAS-004 Phase 1

More from Immuneering

IMM-6-415 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IMRX page.

Follow IMRX, the company behind Atebimetinib

See IMRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z